Nuclear Medicine Department of Acıbadem Healthcare Group deal with use of radioactive-labeled materials in small amounts for diagnosis and treatment of diseases and monitoring the distribution of these materials in the body.
On the contrary to radiology studies that image anatomic details, nuclear medicine is focused on imaging the functions of organ to diagnose diseases.
Nuclear Medicine Department of Acıbadem Healthcare Group are able to image infections and inflammations, disorders of cardio-vascular system, skeletal system, thyroid, parathyroid, genito-urinary system, pulmonary system and central nerve system and tumors and intra-operative sentinel node biopsy procedures.
Moreover, leukocyte-labeled whole-body scintigraphy can also be scanned in our Nuclear Medicine Department.
Efficient screening for tumor detection and treatment
PET/CT is one of today’s most efficient imaging systems. It is used particularly in the field of oncology, in tumor detection, determining the degree of differentiation of the tumor, radiotherapy planning, assessing response to treatment, and in some cases, determining whether the mass is benign or malignant.
As PET/CT imaging allows simultaneous screening of the whole body, it enables determining whether the disease has spread to other organs or not. PET/CT also provides answers to questions as to whether an active disease is still present after the treatment or not; and how efficient the treatment has been.
PET/CT is also used for identifying epileptogenic focus, in neurologic cases such Alzheimer’s disease, and in detection of viable heart tissue following a heart attack.
Gallium 68 is a nuclear medicine agent used for imaging prostate cancer and endocrine tumors (Gallium-PET) at Nuclear Medicine Department. A PET-CT scan is run that lasts for 20 minutes, after Gallium-68 isotope is intravenously administered to the patient and 60-minute uptake phase elapses.
Ga-68 PSMA PET/CT is more successful than PSA, ultrasound, computed tomography and MRI in terms of staging and investigating relapse and metastases in patients with prostate carcioma. And Ga- 68 DOTATATE PET/ CT is more efficient compare with classical imaging methods in patients with increased somatostatine receptor expression such as neuroendocrine tumors, menengiomas, feochromacytoma etc.
It offers high potential benefit in patients with moderate and high risk according to pathologic scoring and staging.
Relapse and metastases identified through Ga-68 PET/ CT can be successfully treated with Lu-177 (lutetium), which is another radionuclide, and this therapy may prolong survival and increase quality of life.
Lutetium 177 therapy is a treatment method developed for patients with neuroendocrine tumor and prostate cancer refractory to hormone therapy.
Lu-177 therapy targets specific treatment of only the cancerous zone. The literature indicate that Lu-77 peptide therapy contributes to longer survival, improved quality of life, alleviation of symptoms and improvement of biochemical markers in patients with somatostatin receptor-positive neuroendocrine tumor. Lu-177 PSMA therapy offers efficient response even in patients with metastatic castration-resistant prostate cancer after majority of other treatment options are used and this well-tolerable therapy has manageable toxicity profile.
Since Lu-177 penetrates into the tissue by below 2 mm, nephrotoxicity is milder. This feature allows limited radiation exposure to bone marrow in patients with diffuse bone metastasis.
It is demonstrated that Lu-177 PSMA therapy alleviates pain in majority of patients with advanced stage prostate cancer and complaint of pain due to metastases.
PSA readings that are used to follow up the prostate cancer decline after the treatment. In the literature, many studies demonstrate that it prolongs survival and increases quality of life in patients with advanced stage prostate cancer.
Lutetium therapy is administered in 4 to 6 cycles at 2- to 4-month intervals. Interpatient variations apply to total number of cycles and inter-cycle intervals.
Iodine unit uses radioactive iodine therapy to manage thyroid cancers in Nuclear Medicine Department of Acıbadem Healthcare Group.
The unit has two patient rooms that are coated with lead for the safety of patients and staff. Rooms are monitored by a nurse with a camera throughout the treatment session. Patients can call nurses and seek information, whenever they want. Nurses visit the patient room at certain intervals to make necessary checks. Excluding the primary doctor and nurse, nobody is allowed to the patient room.